Time to Relapse and the Patterns of Relapse Are Prognostic for Post-Relapse Survival after CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Allogeneic hematopoietic stem cell transplantation (HCT), defined by its underlying graft-versus-multiple myeloma (MM) effect, is a potentially curative approach for high-risk pts. However, relapse remains the main cause of treatment failure. Predictors for post-relapse survival after HCT are not well characterized, and we hypothesized that the time to relapse and the patterns of relapse are prognostic for post-relapse survival.Methods: All pts with MM who underwent a CD34+-selected alloHCT at Memorial Sloan Kettering Cancer Center on protocol (NCT 01131169/01119066) or off study from 01/2010 to 12/2017 and progressed after alloHCT were included.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Alexandra Gomez-Arteaga, Gunjan L. Shah, Raymond E Baser, Josel D. Ruiz, Adam Bryant, David J. Chung, Parastoo B. Dahi, Arnab Ghosh, Oscar Boutros Lahoud, Heather J Landau, Ola Landgren, Molly A. Maloy, Michael Scordo, Brian C. Shaffer, Eric Smith, Guenth Tags: 25 Source Type: research